Healthcare / BiotechnologyNasdaqCM
$2.14
-0.07 (-3.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-24.7M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$11M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-561.2%
↓Gross Margin
N/A
•Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2002–2025 · 23 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-863.8%
FCF / Net income
1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.5M · net income $-21.5M · FCF $-21.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||||||||||
| Revenue | $2.5M | $2.5M | $4.0M | — | $81526.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | $-21.5M | $-21.5M | $-25.0M | $-26.0M | $-14.0M | $-18.6M | $-3.0M | $-2.4M | $-2.6M | $-2.2M | $-3.3M | $-2.7M | $-2.7M | $-2.3M | $-2.1M | $-2.3M | $-2.7M | $-3.3M | $-3.7M | $-4.2M | $-584166.00 | $-1.6M | $-2.4M | $-947804.00 | $-618137.00 |
| EBITDA | $-21.4M | $-21.4M | $-24.9M | $-25.9M | $-14.0M | $-18.7M | $-2.8M | $-2.4M | $-2.5M | $-2.1M | $-3.2M | $-2.7M | $-2.7M | $-2.2M | $-2.0M | $-2.2M | $-2.7M | $-3.2M | — | — | — | — | — | — | — |
| EPS | -22.40 | -22.40 | -120.46 | -357.25 | -311.25 | -1140.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -869.3% | -869.3% | -635.8% | — | -17207.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | -862.3% | -862.3% | -632.0% | — | -17198.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||||||||||
| Debt/Equity | 0.22 | 0.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.06 | 1.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||||||||||
| Free Cash Flow | $-21.5M | $-21.5M | $-24.7M | $-25.2M | $-19.2M | $-11.2M | $-2.9M | $-1.4M | — | $-1.7M | — | $-2.7M | $-2.3M | $-1.8M | $-3.0M | $-315517.00 | $-2.4M | $-1.7M | — | — | — | — | — | — | — |
| Returns | |||||||||||||||||||||||||
| ROE | -561.2% | -561.2% | -495.0% | -450.6% | -52.7% | -425.8% | -30.9% | 150.6% | 250.4% | 675.9% | -1361.1% | -223.3% | -238.5% | -90.4% | -185.5% | -333.5% | -149.6% | -87.7% | -137.6% | -160.2% | -26.5% | 321.8% | 603.8% | -108.6% | 96.7% |
| Valuation | |||||||||||||||||||||||||
| P/B | 0.54 | 0.54 | 2.71 | 1.75 | 0.41 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||||||||||
| Revenue Growth | -37.1% | -37.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | 81.4% | 81.4% | 66.3% | -14.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-91.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-120.46 → -22.40
Residual
-91.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.